New pill combo aims to boost immune attack on tough cancers

NCT ID NCT06362369

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the combination is safe and helps control the disease. About 126 adults will take part in two phases: first finding the right dose, then comparing the combo to standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brown University Health Cancer Institute

    RECRUITING

    Providence, Rhode Island, 02906, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dartmouth Hitchcock

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

    Contact

    Contact Phone: •••-•••-••••

  • Florida Cancer Specialists

    COMPLETED

    Lake Mary, Florida, 32746, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-••••

  • University of Colorado Cancer Center

    RECRUITING

    Aurora, Colorado, 84005, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.